Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee

NAMUR, Belgium, Oct. 17, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at the University of Copenhagen, gave a presentation on "Blood-based biomarkers in possible triaging of FIT (faecal immunochemical test) positive subjects" to the World Endoscopy Organization's Colorectal Cancer Screening Committee meeting in Vienna, Austria on Friday, October 14. This meeting was specifically focused on bringing experts together to discuss recent advances in colorectal cancer screening, as well as future screening initiatives.

Professor Nielsen's presentation examined how Volition's blood-based biomarker Nu.Q™ Colorectal Cancer Screening Triage Test (blood test) could be used in conjunction with the current standard colorectal cancer screening test, the FIT test, to further screen patients with a positive FIT score. Previously released data on this test showed that it has the potential to offer up to a 25% reduction in colonoscopies while maintaining almost 97% detection of colorectal cancer when combined with the FIT score.

Fewer than 10% of people with a positive FIT score have colorectal cancer, as a positive FIT score is not a diagnostic for cancer but means simply that blood has been found in the stool. Currently all patients with a positive FIT score are referred for a colonoscopy for a definitive cancer diagnosis. Consequently, there are a significant number of unnecessary, expensive and invasive colonoscopies performed, placing a burden on both the patient and healthcare system.

Professor Nielsen commented, "There is potentially a huge demand for a test like this because healthcare systems in Denmark and many other countries are struggling to meet the increased colonoscopy demand from colorectal cancer screening programs. Triaging patients with this test could significantly reduce the number of patients being referred for unnecessary colonoscopies, and so would allow more people to be screened for colorectal cancer quickly and effectively."

Louise Day, Chief Marketing and Communications Officer said, "It was great for us to take part in this meeting where experts from 14 countries presented and many more came together to discuss the current state of colorectal cancer screening. We can certainly see how our Nu.Q™ Triage Test could help alleviate some of the challenges current screening programs face."

About Volition

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q^TM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

SOURCE VolitionRx Ltd.

Related Links

http://www.volitionrx.com